Table 1. Stage Tis, Ta mRNA Cohort – 189 Patients.
Characteristic | N (%) |
---|---|
Median Age (IQR) | 67 (58-74) |
Male | 154 (81) |
High Grade* | 64 (34) |
CIS+ | 17 (9) |
EORTC High-Risk Group | 67 (35) |
Median Follow-up in Years (IQR) | 4.8 (3.4-6.7) |
Progression to T2 | 21 (11) |
Deaths | 57 (30) |
2004 World Health Organization grade definitions
** European Organisation for Research and Treatment of Cancer